Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
BIA 3-202 is a novel catechol-O-methyltransferase (COMT) inhibitor being developed for use as a levodopa-sparing agent in Parkinson's disease. This study investigated the effect of four single oral doses of BIA 3-202 (50 mg, 100 mg, 200 mg, and 400 mg) compared with placebo on plasma concentrations of levodopa and its metabolite 3- O-methyl-levodopa (3-OMD) and on inhibition of erythrocyte COMT in healthy subjects receiving 100 mg of levodopa and 25 mg of benserazide (Madopar 125). This was a single-centre, double-blind, placebo-controlled, randomised, crossover study with five single-dose treatment periods. The washout period between doses was 2 weeks. On each treatment period, a different dose of BIA 3-202 or placebo was administered concomitantly with Madopar 125. Tolerability was assessed by recording adverse events, vital signs, continuous electrocardiogram and clinical laboratory parameters. In the study, 18 subjects (12 male and 6 female) participated. The drug combination was well tolerated. All doses of BIA 3-202 significantly increased the area under the concentration-time curve (AUC) versus placebo, ranging from 39% (95% confidence intervals, 1.06-1.69) with 50 mg to 80% (95% confidence intervals, 1.42-2.22) with 400 mg. No significant change in mean maximum plasma concentrations (C(max)) of levodopa was found. Mean C(max) and AUC of 3-OMD significantly decreased for all doses tested. BIA 3-202 caused a rapid and reversible inhibition of S-COMT activity, ranging from 57% (50 mg) to 84% (400 mg). In conclusion, the novel COMT inhibitor BIA 3-202 was well tolerated and significantly increased the bioavailability of levodopa and reduced the formation of 3-OMD when administered with standard release levodopa/benserazide.
D000098:Acetophenones / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000293:Adolescent; D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology*; D019540:Area Under Curve; D001545:Benserazide / Q000009:adverse effects / Q000494:pharmacology*; D065098:Catechol O-Methyltransferase Inhibitors; D018592:Cross-Over Studies; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives* / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004338:Drug Combinations; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D014443:Tyrosine / Q000031:analogs & derivatives
D000098:Acetophenones; D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D004338:Drug Combinations; D014443:Tyrosine; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D001545:Benserazide; C433466:nebicapone; C008404:3-methoxytyrosine